https://dora.health.qld.gov.au/qldresearchjspui/handle/1/15 Sat, 14 Mar 2026 13:04:31 GMT 2026-03-14T13:04:31Z https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6202 Title: CERAMIDE EVOKES AN APOPTOTIC INTEGRATED STRESS RESPONSE IN ACUTE MYELOID LEUKEMIA Authors: Craig Wallington-Gates; Jason Powell; Alexander Lewis; Melinda Tea; Thao Nguyen; Dovile Anderson; Darren Creek; Richard D'Andrea; David Ross; Daniel Thomas; Stuart Pitson Tue, 01 Jan 2019 00:00:00 GMT https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6202 2019-01-01T00:00:00Z https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6201 Title: Sphingolipids and the unfolded protein response Authors: Bennett, Melissa K; Wallington-Gates, Craig; Pitson, Stuart M Abstract: The unfolded protein response (UPR) is a response by the endoplasmic reticulum to stress, classically caused by any disruption to cell homeostasis that results in an accumulation in unfolded proteins. However, there is an increasing body of research demonstrating that the UPR can also be activated by changes in lipid homeostasis, including changes in sphingolipid metabolism. Sphingolipids are a family of bioactive lipids with important roles in both the formation and integrity of cellular membranes, and regulation of key cellular processes, including cell proliferation and apoptosis. Bi-directional interactions between sphingolipids and the UPR have now been observed in a range of diseases, including cancer, diabetes and liver disease. Determining how these two key cellular components influence each other could play an important role in deciphering the causes of these diseases and potentially reveal new therapeutic approaches. Tue, 01 Oct 2019 00:00:00 GMT https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6201 2019-10-01T00:00:00Z https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6200 Title: Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma Authors: Craig Wallington-Gates; Lisa M. Ebert; Kate Vandyke; M. Zahied Johan; Mark DeNichilo; Lih Y. Tan; Kay K. Myo Min; Benjamin M. Weimann; Brenton W. Ebert; Stuart M. Pitson; Andrew C. W. Zannettino; Claudine S. Bonder Fri, 01 Jan 2021 00:00:00 GMT https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6200 2021-01-01T00:00:00Z https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6199 Title: Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma Authors: Mynott, Rachel L; Wallington-Gates, Craig Abstract: Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters. Fri, 11 Jun 2021 00:00:00 GMT https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6199 2021-06-11T00:00:00Z